本研究在体证实了MSA中存在胆碱能通路特异性损伤，尤其PPN-丘脑通路作为运动调控关键枢纽，其损伤程度与疾病严重度密切关联。该发现不仅深化了对MSA病理机制的理解，也为未来开发胆碱能通路靶向治疗策略提供了影像学依据。团队下一步将推进多中心纵向研究，验 ...

Now, I’m also experiencing more consistent, significant autonomic dysfunction, with a myriad of other symptoms. In May 2024, ...

Tiziana Life Sciences (TLSA) announces the submission of its seventh annual Development Safety Update Report to the U.S. Food ...

MSA作为一种进展性神经退行性疾病，其病理核心为α-突触核蛋白在少突胶质细胞中异常沉积形成的胶质胞质包涵体。既往尸检研究提示脑干脚桥核（PPN）和基底前脑Meynert核（NBM）的胆碱能神经元显著丢失，但对其投射通路的在体评估及临床关联仍缺乏系统研究。 团队纳入103例MSA患者与44名健康对照者，通过多模态磁共振数据重建三条关键胆碱能通路：NBM-内侧皮层通路（经扣带回）、NBM-外侧皮层通路 ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

Tiziana Life Sciences ( ($TLSA) ) just unveiled an update. On December 29, 2025, Tiziana Life Sciences reported that it has filed its seventh ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi's tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec.

Summary • Tiziana Life Sciences Ltd’s stock rises 6% in pre-market trading to $1.65 after submitting their annual Development ...

A foster mother who took in Armenta and Lemke's other children is speaking out about the steps they took to help prevent the ...

The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

《柳叶刀-神经病学》（The Lancet ...